Tempus Labs is a technology company in Chicago founded in the year 2015 by a philanthropist, investor and entrepreneur, Eric Lefkofsky. The company’s objective is to develop the most extensive molecular and clinical data library in the world with an operating system that makes the data accessible and useful to expertise physicians treating cancer patients. Tempus is one of the Chicago’s top ten healthcare techs providing quality services. It has, therefore, received unicorn funding status.
With the modern tech lab equipment, Tempus Unicorn uses data as means of improving treatment efficiency and helps personalize cancer care. The Tempus Chief Executive Officer, Lefkofksy said on Tuesday 20th of March 2018 that the firm had received eighty million dollars in funding from a group of new and existing investors. As the Tempus develops, it uses Unicorn funding to expand its reach by adding more employees on a monthly basis. Lefkofsky confirmed that its firm employs workers at an extremely high rate and expect the pace to continue despite having about 400 employees at the moment.
Tempus Unicorn has so far received $210 million investment courtesy of the Groupon co-founder Eric Lefkofsky. The latest fundraising round from new and existing investors puts the company at a value approximately $1.1 billion. The contributors of March funding round included Revolution Growth, New Enterprise Associates and New investors Kinship Trust Co. Intuitively, funds deliberated by T. Rowe Price Associates.
The organization uses clinical data in discovering both the trends in the treatment of cancer and also collecting molecular data mainly from patients under diagnosis. Data collected in medicals are essential since doctor’s handwritten patients’ notes get digitalized so that they available and easily stored in the computer database to expand treatment options.
Lefkofsky through the Chicago Business insider said that the company has relationships with organizations and individuals in all series of the health care system, including drug companies and also doctors looking for an effective method to use extensive data to treat cancer patients. Tempus is proud of the traction it has built with the members in the industry which includes all the organizations it partnered to create a pathway of attaining its goals through sequencing, machine learning and bioinformatics.
To Learn More Click Here